Immunity With Acute Hepatits A

Launched by ASSIUT UNIVERSITY · Apr 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the body’s immune system responds to the Hepatitis A Virus (HAV) in children. Hepatitis A is a liver infection that is a significant health concern in Egypt, especially among kids. The trial aims to understand the effects of the virus since many children may be exposed to it by age 15, even though it often causes mild symptoms in younger kids. By looking at how the immune system reacts to this virus, researchers hope to find better ways to manage and prevent the infection.

To participate in this trial, children aged 1 to 15 years who have been diagnosed with acute hepatitis A and are currently hospitalized for treatment may be eligible. However, kids with certain health issues, like pre-existing liver disease or other specific infections, cannot join. Parents or guardians will need to provide consent, and the children will be informed about the study in a way that they can understand. Participants can expect to receive care for their condition while contributing valuable information to help improve future treatments and prevention strategies for hepatitis A.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children aged 1-15 years
• • Confirmed diagnosis of acute hepatitis A infection (positive anti-HAV IgM)
• • Admitted to the hospital for management of acute hepatitis A
• • Parental/guardian consent and child assent (where appropriate) obtained
• Exclusion Criteria:
• • Known pre-existing liver disease or chronic hepatitis
• • Immunodeficiency disorders or current immunosuppressive therapy
• • Coinfection with other hepatotropic viruses (HBV, HCV, HEV)
• • Severe malnutrition
• • Recent blood transfusion (within 3 months)